Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): a randomized, multicenter, phase III clinical trial.
Sarkar S, Bokade C, Garg K, Kumar R, Sanmukhani J, Mittal R. Sarkar S, et al. Among authors: sanmukhani j. Hum Vaccin Immunother. 2021 Mar 4;17(3):681-689. doi: 10.1080/21645515.2020.1794683. Epub 2020 Aug 26. Hum Vaccin Immunother. 2021. PMID: 32845782 Free PMC article. Clinical Trial.
Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial.
Sharma S, Singh VB, Kumar S, Prajapati V, Patel J, Vukkala R, Jangid SK, Sanmukhani J, Gupta G, Patel P, Mittal R, Glueck R. Sharma S, et al. Among authors: sanmukhani j. Hum Vaccin Immunother. 2018 Jun 3;14(6):1362-1369. doi: 10.1080/21645515.2018.1441654. Epub 2018 Mar 21. Hum Vaccin Immunother. 2018. PMID: 29461913 Free PMC article. Clinical Trial.
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India.
Momin T, Kansagra K, Patel H, Sharma S, Sharma B, Patel J, Mittal R, Sanmukhani J, Maithal K, Dey A, Chandra H, Rajanathan CT, Pericherla HP, Kumar P, Narkhede A, Parmar D. Momin T, et al. Among authors: sanmukhani j. EClinicalMedicine. 2021 Aug;38:101020. doi: 10.1016/j.eclinm.2021.101020. Epub 2021 Jul 17. EClinicalMedicine. 2021. PMID: 34308319 Free PMC article.
Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
Sood A, Mitra M, Joshi HA, Nayak US, Siddaiah P, Babu TR, Mahapatro S, Sanmukhani J, Gupta G, Mittal R, Glueck R. Sood A, et al. Among authors: sanmukhani j. Hum Vaccin Immunother. 2017 Jul 3;13(7):1523-1530. doi: 10.1080/21645515.2017.1302629. Epub 2017 Mar 31. Hum Vaccin Immunother. 2017. PMID: 28362563 Free PMC article. Clinical Trial.
Clindamycin 1% Nano-emulsion Gel Formulation for the Treatment of Acne Vulgaris: Results of a Randomized, Active Controlled, Multicentre, Phase IV Clinical Trial.
Bhavsar B, Choksi B, Sanmukhani J, Dogra A, Haq R, Mehta S, Mukherjee S, Subramanian V, Sheikh S, Mittal R. Bhavsar B, et al. Among authors: sanmukhani j. J Clin Diagn Res. 2014 Aug;8(8):YC05-9. doi: 10.7860/JCDR/2014/9111.4769. Epub 2014 Aug 20. J Clin Diagn Res. 2014. PMID: 25302253 Free PMC article.
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.
Khobragade A, Bhate S, Ramaiah V, Deshpande S, Giri K, Phophle H, Supe P, Godara I, Revanna R, Nagarkar R, Sanmukhani J, Dey A, Rajanathan TMC, Kansagra K, Koradia P; ZyCoV-D phase 3 Study Investigator Group. Khobragade A, et al. Among authors: sanmukhani j. Lancet. 2022 Apr 2;399(10332):1313-1321. doi: 10.1016/S0140-6736(22)00151-9. Lancet. 2022. PMID: 35367003 Free PMC article. Clinical Trial.
Tretinoin Nanogel 0.025% Versus Conventional Gel 0.025% in Patients with Acne Vulgaris: A Randomized, Active Controlled, Multicentre, Parallel Group, Phase IV Clinical Trial.
Chandrashekhar BS, Anitha M, Ruparelia M, Vaidya P, Aamir R, Shah S, Thilak S, Aurangabadkar S, Pal S, Saraswat A, Sanmukhani JJ. Chandrashekhar BS, et al. Among authors: sanmukhani jj. J Clin Diagn Res. 2015 Jan;9(1):WC04-9. doi: 10.7860/JCDR/2015/10663.5469. Epub 2015 Jan 1. J Clin Diagn Res. 2015. PMID: 25738069 Free PMC article.
20 results